Sangamo Therapeutics, Inc. (SGMO)

0.443 -0.01 (-1.60%) USD  |  NASDAQ  |  Jan 09, 16:00
0.4501 +0.01 (+1.60%) Pre-Market: 20:00
More

Sangamo Therapeutics Research and Development Expense (% of Annual Revenues)

Research and Development Expense (% of Annual Revenues) Chart

View Research and Development Expense (% of Annual Revenues) for SGMO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (% of Annual Revenues) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (% of Annual Revenues) Range, Past 5 Years

View Research and Development Expense (% of Annual Revenues) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (% of Annual Revenues) Benchmarks

View Research and Development Expense (% of Annual Revenues) Benchmarks
Start Trial
Arcturus Therapeutics Holdings, Inc. Upgrade
AIM ImmunoTech, Inc. Upgrade
Perspective Therapeutics, Inc. Upgrade
Protalix Biotherapeutics, Inc. Upgrade
Armata Pharmaceuticals, Inc. Upgrade